Notfälle
Blutspende
Karriere
Presse
Forschung
Lehre
Patienten
Zuweiser

Singer K, Kastenberger M, Gottfried E, Hammerschmied C, Büttner M, Aigner M, Seliger B, Walter B, Schlösser H, Hartmann A, Andreesen R, Mackensen A, Kreutz M. Warburg phenotype in renal cell carcinoma: High expression of glucose-transporter 1 (GLUT-1) correlates with low CD8+ T cell infiltrate in the tumor. Int J Cancer. 2011; 128:2085-95.

 

Bukur J, Herrmann F, Handke D, Recktenwald C, Seliger B. E2F1 – a transcriptional attenuator of tapasin expression downregulated in oncogene transformed cells. J Biol Chem 2010; 285:30419-26.

 

Masucci G, Andersson E, Villabona L, Helgadottir H, Bergfeldt K, Cavallo F, Forni G, Ferrone S, Aniruddha C, Seliger B, Kiessling R. Survival of the fittest or best adapted HLA-dependent tumor development. J Nucleic Acids Inv. In press.

 

Mimura K, Ando T, Poschke I, Mougiakakos D, Johansson C, Ichikawa J, Okita R, Nishimura M, Handke D, Krug N, Choudhury A, Seliger B, Kiessling R. T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2/neu. Int J Cancer 2011; 128:390-401.

 

Quandt D, Massa C, Seliger B. "Tumor immunology meets oncology (TIMO) VI" from 7th to 8th of May 2010 in Halle, Germany. Cancer Immunol Immunother 2011; 60:299-303.

 

Croci S, Recktenwald CV, Lichtenfels R, Nicoletti G, Dressler SP, De Giovanni C, Astolfi A, Palladini A, Shin-ya K, Landuzzi L, Nanni P, Lollini PL, Seliger B. Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system. Proteomics. 2010; 10:3835-53. 

 

Amiot L, Ferrone S, Grosse-Wilde H, Seliger B. Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention? Cell Mol Life Sci. 2011; 68:417-31.

 

Seliger B, Jasinski S, Dressler SP, Marincola FM, Recktenwald CV, Wang E, Lichtenfels R. Linkage of microRNA and proteome-based profiling data sets: a perspective for the priorization of candidate biomarkers in renal cell carcinoma? J Proteome Res. 2011; 10:191-9.

 

Hase S, Weinitschke K, Fischer K, Fornara P, Hoda R, Unverzagt S, Seliger B, Riemann D. Monitoring peri-operative immune suppression in renal cancer patients. Oncol Rep. 2011; 25:1455-1464.

 

Respa A, Bukur J, Ferrone S, Pawelec G, Zhao Y, Wang E, Marincola FM, Seliger B. Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines. Clin Cancer Res. 2011; 17:2668-2678.

 

Quandt D, Fiedler E, Boettcher D, Marsch W and Seliger B. 1B7-H4 expression in human melanoma: its association with patients’ survival and anti tumor immune response. Clin Cancer Res. 2011;17 :3100-11.

 

Seliger B, Dressler S, Massa C, Recktenwald C, Altenberend F, Bukur J, Wang E, Stevanovic S, Lichtenfels R. Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells. Proteomics. 2011; 11:2528-41.

 

Rappl G, Pabst S, Riemann D, Schmidt A, Wickenhauser C, Schütte W,  Hombach A, Seliger B, Grohé C, Abken H. Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation. Clin Immunol. 2011; 140:71-83.

 

Croci S, Recktenwald CV, Lichtenfels R, Nicoletti G, Dressler SP, De Giovanni C, Astolfi A, Palladini A, Shin-Ya K, Landuzzi L, Nanni P, Lollini PL, Seliger B. Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system. Proteomics Clin Appl. 2011; 5:200. 

 

Bormann F, Sers C, Seliger B, Handke D, Bergmann T, Seibt S, Lehrach H, Dahl A. Methylation-specific ligation detection reaction (msLDR): a new approach for multiplex evaluation of methylation patterns. Mol Genet Genomics. 2011 Aug 31. [Epub ahead of print].

 

Bukur J, Noessner E, Seliger B"Tumor immunology meets oncology (TIMO) VII" from 15th to 16th of April 2011 in Halle/Saale, Germany. Cancer Immunol Immunother. 2011 Sep 11. [Epub ahead of print].

 

Gebler A, Zabel O, Seliger BThe immunomodulatory capacity of mesenchymal stem cells. Trends in Molecular Medicine. 2011 Nov 25. [Epub ahead of print]

 

Fox, B.A., Schendel, D., Butterfield, L.H., Allison, J., Ascierto, P.A., Atkins, M.A, Bartunkova, J., Bergmann, L., Bramson, J., Britten, C. M., Carson W.E., Characiejus, D., Choudhury, R., Coukos, G., Finke, J., Gollob,J.A., Gouttefangeas, C., Grizzi, F., Guida, M., Haakanson, L., Hege, K., Hodi, F. S., Hoos, A., Hwu, P., Kaufman, H., Kawakami, K., Kawakami, Y., Khleif, S., Kiessling, R., Y., Jaffee, E.M., Janetski, S., June, C.H., Lapointe, R., Levitsky, H., Maio, M., Murphy, W., Maccalli, C., Masucci, G., Nelson, B., Nicolini, A., Ohashi, P.S., Ottensmeier, C., Papamichail, M., Parmiani, G., Pawelec, G., Proietti, E., Qin, S., Ribas, A., Rivoltini, L., Romero, P., Sharma, P., Seliger, B., Shiku, H., Song, W.R., Stratten, P.T., Tahara, H., van der Burg, S. H., von Hoegen, P., Wang, E., Welters, M., Wolchok, J., Zweirzina, H., L. Marincola, F., Gajewski, T., Wigginton, J., Disis, M.L. Defining the Critical Hurdles in Cancer Immunotherapy. J Transl Med. 2011; 9:214.

 

Seliger B. Novel insights into the molecular mechanisms of HLA class I abnormalities. Cancer Immunol Immunother. 2011; 61:249-54.